Bio-Chem Pharma (BCHXF) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bio-Chem Pharma (BCHXF)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jbershad who wrote (8)	7/28/1996 9:13:00 PM
From: jbershad	of 43

This is the first time such significant reductions in the viral burden have been shown. Clearly the protease inhibitors enhance the activity of 3TC/AZT considerably. Importantly, the fact that this work has been done with3TC/AZT and not other reverse transcriptase inhibitor combinations underscores 3TC/AZT as a conerstone in all combinations therapies for AIDS. As for a Hepatitus B law suit there is none I could find. The law suite involving Emory Univ. is not considered major and chances are it will be overturned. Glaxo has made this clear. When I reply again I will try to gather info on the socio-economic problem you spoke of. In the meantime I appreciate all replies and welcome your thoughts. Latest earnings estimates for BCHXF are $0.56 on revenues of 233 million for 96. $1.16 EPS on revenues of 284 million for 97 This does not include any Hepatitus sales at all. The revenues for these are expected to be larger. Jerry

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next